507. Impact of Baricitinib on Outcomes in Patients Treated with Remdesivir and Dexamethasone for SARS-CoV-2 Pneumonia: A Retrospective Cohort Study

BACKGROUND: There is a lack of data specifically addressing the effects of triple therapy consisting of baricitinib plus remdesivir plus dexamethasone compared to dual therapy with remdesivir plus dexamethasone among patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pneumoni...

Descripción completa

Detalles Bibliográficos
Autores principales: Dea, Lauren, Piwonka, Hal, Gonzales, Learned, Kerkar, Shubha, Mdluli, Xolani, Kim, Yisu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644669/
http://dx.doi.org/10.1093/ofid/ofab466.706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644669/
http://dx.doi.org/10.1093/ofid/ofab466.706

Ejemplares similares